Literature DB >> 12861444

Emotional expressiveness and the quality of life of patients with schizophrenia.

A R Mubarak1, J G Barber.   

Abstract

BACKGROUND: The present research aims to study the association between emotional expressiveness of primary care-givers and quality of life of patients with schizophrenia.
METHOD: The data for the present study were collected from 174 purposively selected patients with schizophrenia and their primary care-givers. The Quality of Life Interview (QOLI) (Lehman 1988) was used to collect information related to the quality of life of patients. The care-givers' emotional expressiveness was assessed using three questions on home environment from Disability Assessment Schedule (WHO/DAS) (WHO 1988).
RESULTS: Three components of emotional expressiveness were included in the present research, namely, emotional involvement, control and attitude of rejection. Among these three components, emotional involvement of key care-givers was found to have a significant association with quality of life of schizophrenia patients.
CONCLUSION: Based on this result, the present study argues that emotional involvement of key care-givers needs careful attention while planning psychosocial rehabilitation programmes aimed at enhancing the quality of life of schizophrenia patients.

Entities:  

Mesh:

Year:  2003        PMID: 12861444     DOI: 10.1007/s00127-003-0645-0

Source DB:  PubMed          Journal:  Soc Psychiatry Psychiatr Epidemiol        ISSN: 0933-7954            Impact factor:   4.328


  2 in total

Review 1.  Quality of life in caregivers of patients with schizophrenia: a literature review.

Authors:  Alejandra Caqueo-Urízar; José Gutiérrez-Maldonado; Claudia Miranda-Castillo
Journal:  Health Qual Life Outcomes       Date:  2009-09-11       Impact factor: 3.186

Review 2.  The role of family therapy in the management of schizophrenia: challenges and solutions.

Authors:  Alejandra Caqueo-Urízar; Mar Rus-Calafell; Alfonso Urzúa; Jorge Escudero; José Gutiérrez-Maldonado
Journal:  Neuropsychiatr Dis Treat       Date:  2015-01-14       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.